Company Announcements - 2014
-
PeriCoach Social Media Marketing Update24 December 2014
Analytica presents an update on PeriCoach activity in Social Media.
-
Change of Director's Interest19 December 2014
Appendix 3Y - Dr Michael Monsour.
-
Change of Director's Interest18 December 2014
Appendix 3Y - Dr Michael Monsour.
-
PeriCoach Update17 December 2014
Analytica ramps up PeriCoach marketing campaign. Apple app under App Store review. Highly targeted online PR and advertising campaign commences. Clinical trial to begin recruitment next month.
-
Annual General Meeting27 November 2014
Analytica presents the Chairman and CEO's addresses and a promotional video from this evening's AGM in Brisbane
-
Patersons Securities Research Note24 November 2014
Analytica is pleased to advise the release of an independent research report from Patersons Securities dated 24 November 2014
-
PeriCoach Product Released24 November 2014
Analytica Limited announces the consumer introduction of PeriCoach.
-
Product Release Update13 November 2014
Analytica Limited advises that the updated, dual-operating system product version has its first batch in the final stages of production and is awaiting final iOS app approvals from Apple Inc.
-
Appendix 3Y11 November 2014
Change of Director's Interest - 4 Notices.
-
Notice under s708A of the Corporations Act7 November 2014
-
Prominent US Healthcare PR firm to drive PeriCoach global campaign7 November 2014
Analytica has appointed US specialist healthcare marketing communication agency jacobstahl Inc. to promote the launch of the PeriCoach System.
-
Appendix 3B - New Issue6 November 2014
Analytica advises that a further 9,984,332 ordinary shares have been privately placed to sophisticated investors at $0.03 per share, raising a further $300k.
-
Appendix 4C - Quarterly Cash Flow31 October 2014
Analytica presents its Appendix 4C for the quarter ended 30th September 2014.
-
Successful Completion of Entitlement Offer31 October 2014
Analytica is pleased to announce that its 1 for 8, $3.17m Entitlement Offer at 3.0 cents per share, has been very well supported by shareholders, with shareholders applying for 85,540,964 shares raising approximately $2.56M. Shares will be allotted on Wednesday 5th November 2014.
-
Analytica Prepares for PeriCoach Clinical Trial29 October 2014
Analytica is pleased to announce that it has completed the design of the Clinical Trial for the PeriCoach system. This multi-centre, randomised, controlled study intends to evaluate the efficacy of the PeriCoach system in females with stress urinary incontinence compared to unassisted pelvic floor exercise as well as the degree of user satisfaction in terms of outcome, ease of use, and improvement in sexual function.
-
Notice of 2014 AGM and Proxy Form24 October 2014
The AGM will be held Thursday, 27 November 2014 at 6.00pm (Brisbane time), at the Endeavour 1 Room, Level 1, Christie Corporate, 320 Adelaide Street, Brisbane.
-
Analytica Recieves $989k R and D Tax Incentive24 October 2014
-
Entitlement Offer – Despatch of Offer Booklet and Entitlement and Acceptance Form17 October 2014
-
Shareholder Information Evenings14 October 2014
Analytica invites shareholders and investors to a series of presentation evenings to be held around Australia in the week starting 20 October.
-
MOU signed with Sportsmed Global13 October 2014
Analytica and SportsMed Global announce a non-binding Memorandum of Understanding to pursue detailed planning for the integration of the PeriCoach pelvic floor exercise system and the SportsMed system.
-
PeriCoach CE Mark Granted9 October 2014
Analytica is pleased to announce that the PeriCoach system received CE-Mark clearance overnight. This major milestone allows Analytica to legally market the PeriCoach system in Europe.
-
Entitlement Offer8 October 2014
A partially underwritten pro-rata non-renounceable entitlement offer of 1 for 8 at an issue price of $0.03 to raise ~$3.17m.
-
Capital Raising announcement and Investor Presentation3 October 2014
Analytica is pleased to announce that it is undertaking an equity capital raising to raise approximately $4.01 million (before offer costs) in conjunction with Lead Manager, Patersons Securities Limited.
-
Appendix 3B - Entitlement Offer3 October 2014
New issue announcement, application for quotation of additional securities and agreement.
-
Extended Voluntary Suspension from Quotation1 October 2014
Analytica has requested a further suspension from quotation pending an announcement by the Company of a capital raising.
-
Further Suspension from Quotation30 September 2014
Analytica has requested a further suspension from quotation pending an announcement by the Company of a capital raising.
-
Trading Halt29 September 2014
Analytica has requested a trading halt pending the announcement by the Company of capital raising.
-
Annual Report26 September 2014
Analytica directors present their Annual Report for the year ending 30 June 2014
-
Bioshares Article22 September 2014
Analytica appears in the 19 Sept edition of Bioshares
-
Patersons Securities Research Note19 September 2014
Analytica is pleased to advise the release of an independent research report from Patersons Securities dated 19 September 2014
-
PeriCoach Marketing and Sales Update17 September 2014
Analytica provides this update on preparations for the general release of the Dual-OS PeriCoach product in October.
-
Appendix 3Y9 September 2014
Change of Director’s Interest Notice.
-
PeriCoach Shareholder Update4 September 2014
Analytica is pleased to provide you with a PeriCoach progress update.
-
Appendix 4E29 August 2014
Preliminary Final Report.
-
Analytica Announces Clinical Advisory Boards19 August 2014
Analytica is pleased to announce the composition of its Clinical Advisory Boards in Australia and the United States.
-
Appendix 4C31 July 2014
Quarterly Cash Flow to 30 June
-
PeriCoach Shareholder Update2 July 2014
-
Herald Sun "In the Black"11 June 2014
An article by John Beveridge covering Analytica in Melbourne's Herald Sun
-
Form 604 - Change of Interest of Substantial Shareholder4 June 2014
-
Patersons Securities Research Note2 June 2014
Analytica is pleased to advise the release of an independent research report from Patersons Securities dated 30 May 2014
-
PeriCoach Production Commences29 May 2014
Analytica has commenced production of the PeriCoach sensor devices on schedule with first domestic sales expected in the next few weeks.
-
Appendix 3Y (x3)28 May 2014
Change of Director’s Interest Notice.
-
PeriCoach App Released in Preparation for First Sales27 May 2014
Analytica is pleased to announce that the PeriCoach app is now available for download for Android devices on the Google Play Store in preparation for imminent production and first sales.
-
PeriCoach Progress Update23 May 2014
An update on progress and next steps, including an explanation of the upcoming PeriCoach Controlled Market Release.
-
Appendix 3B (with Correction)22 May 2014
New issue announcement, application for quotation of additional securities and agreement.
-
Fund Raising Completion20 May 2014
Analytica is pleased to announce that its underwritten 1 for 15 $1.2m Entitlement Offer at 2.4 cents a share, has been very well supported by shareholders, with shareholders applying for $831k of shares.
-
Appendix 3Y9 May 2014
Change of Director's Interest Notice.
-
Reimbursement of Urinary Incontinence Health Costs In USA and Australia. Outstanding Value.7 May 2014
An exciting and critical milestone just reached is the completion of an independent reimbursement report commissioned by Analytica for the US market.
-
Rights Issue Documentation6 May 2014
Documentation for the Rights Issue: - Chairman's letter, Entitlement Offer Booklet, Acceptance Form and Brochure.
-
Sky Business Interview with Geoff Daly23 April 2014
Nigel Freitas speaks with Analytica CEO Geoff Daly on Sky Business Technology Behind Business.
-
Appendix 4C - Quarterly cash Flow30 April 2014
Analytica presents its Appendix 4C for the quarter ended 31st March 2014.
-
Rights Issue23 April 2014
1 for 15 rights issue to eligible shareholders at $0.024 per share.
-
Section 708A Notice and Appendix 3B23 April 2014
75m ordinary shares issued for recent private placement
-
Capital Raising up to $3m in Private Placement and Rights Issue22 April 2014
$1.8m private placement to sophisticated investors at $0.024 per share. 1 for 15 rights issue to existing investors at $0.024 per share. Funding to accelerate marketing of PeriCoach™ which launches this quarter. Included is an investor presentation used during the capital raising.
-
Trading Halt for Capital Raise16 April 2014
Analytica requests a trading halt from the commencement of trading on Wednesday 16th April 2014, pending the announcement of a capital raising.
-
Shareholder PeriCoach Update Newsletter8 April 2014
-
PeriCoach Marketing Activity Update1 April 2014
An update on PeriCoach marketing activity from the CEO.
-
Appendix 3Y31 March 2014
Change of Director's Interest
-
PeriCoach Product Development Update31 March 2014
An update on PeriCoach product development progress from the CEO.
-
Appendix 3Y (x2)17 March 2014
Change of Director's Interest
-
Bryan Dulhunty Appointed as Analytica CFO12 March 2014
Analytica has appointed Bryan Dulhunty B.Ec, ACA as Chief Financial Officer, in addition to his role as Company Secretary of Analytica.
-
News Article5 March 2014
Analytica features in an Article by John Beveridge of Melbourne's Herald Sun: "Huge potential for Aussie medical device".
-
Appendix 4D and Half Year Report28 February 2014
Half Year Report for the 6 months ended December 2013.
-
Analytica article in Bioshares17 February 2014
Extract article covering Analytica from Bioshares #539
-
Investor Presentation13 February 2014
Analytica Ltd presents an updated investor brief for a number of stockbroking organisations and other potential investors over the next few weeks.
-
Geoff Daly Appointed CEO12 February 2014
Analytica has appointed Geoff Daly as Chief Executive Officer effective immediately as the company positions itself for the launch of its lead product PeriCoach™ during 2014.
-
Appendix 3B12 February 2014
Incentive options on CEO Appointment.
-
Carl Stubbings Appointed Non-Executive Director13 January 2014
Analytica Limited has appointed biotech industry veteran Carl Stubbings as a nonexecutive director, contributing his considerable skills of international marketing, strategic planning and commercialisation
-
Appendix 3X13 January 2014
Initial Director’s Interest Notice - Carl Stubbings